The "Natural Ozempic" Headline Spain Keeps Writing, Minus the One Number That Matters

Berberine has spent three years cycling through the same media loop. A TikTok wave in 2023 pushed the hashtag past 100 million views, built almost entirely on creator testimonials rather than clinical data. CNN, TIME, and CBC all ran pieces debunking the "natural Ozempic" framing within months, with doctors quoted calling it a marketing triumph. El Mundo's Yo Dona vertical is the latest entry in that recurring genre, this time asking pharmacists Sento Segarra and Carmen Palos, plus doctors Isabel Viña Bas and Álvaro Campillo, to weigh in on whether the nickname holds up.

Their answer, buried in careful hedging, is a soft no. The article positions berberine as a third-tier option behind diet and lifestyle changes but ahead of prescription drugs, and it recommends the HCl form at 97% purity or higher, taken in 8-to-12-week courses. Campillo makes the mechanistic distinction explicit: berberine activates AMPK, the same pathway family targeted by metformin, and improves insulin sensitivity and lipid profiles. Semaglutide, by contrast, works as a GLP-1 receptor agonist acting on appetite centers in the brain. Some research shows berberine can raise postprandial GLP-1 levels by 20 to 35 percent indirectly, but that's a downstream effect, not receptor agonism.

What the article never does is put a number next to that distinction. A set of 2025 meta-analyses found berberine produces roughly 0.88 kilograms of weight loss and a BMI reduction of 0.48 compared with placebo. Semaglutide's STEP trials showed 12 to 15 percent body weight loss over 68 weeks. That gap is roughly an order of magnitude, and it's the single fact that would have settled the headline's question in one sentence.

The safety picture gets similarly thin treatment. Berberine's known GI side effects make it into the piece, but its drug-interaction profile doesn't get the space it deserves. The compound inhibits CYP3A4, 2D6, and 2C9 enzymes, which can raise blood levels of statins, diabetes medications, and benzodiazepines — a combination with statins carries real cardiotoxicity risk through CYP3A4 and hERG channel effects. Spain's OCU consumer organization flagged berberine side effects back in January 2025, and reporting from Merca2 points to a 2026 AEMPS alert about plant-extract products exceeding EU safety limits, though that alert's primary text wasn't locatable at the source. Berberine remains unapproved by the FDA or EMA as a weight-loss product anywhere; it's classified as a supplement, which is a different regulatory bar than the one semaglutide clears.

None of this happens in a vacuum. Ozempic has been prescription-restricted to diabetes patients in Spain since November 2022, and chronic shortages tied to off-label weight-loss demand have followed ever since. Semaglutide was Spain's top public pharmaceutical expenditure line in 2024, at €403.9 million, up 36 percent year over year. Wegovy still isn't funded by Spanish social security as of May 2026, after three rejections. That cost and access gap is the more interesting story sitting just outside the frame of El Mundo's piece — a plausible explanation for why a compound producing a fraction of a kilogram's difference from placebo keeps finding an audience willing to call it the natural version of a drug that works ten times harder.